SANTA ANA, Calif. -- Advanced Medical Optics, Inc. (AMO)
has announced that it has entered into a patent cross-licensing agreement
with Alcon, Inc. relating to lubricious coatings for intraocular lens
(IOL) inserters and one-piece IOL haptic designs. AMO is granting a license
to Alcon to AMO's U.S. Patent Nos. 5,803,925, entitled "IOL
Insertion Apparatus with Covalently Bonded Lubricant," and 5,716,364,
entitled "IOL Insertion Apparatus and Method for Making and Using
Same," and related foreign patents. Alcon is granting AMO a license
to Alcon's U.S. Patent No. 5,716,403, entitled "Single Piece
Foldable Intraocular Lens," and related foreign patents, in so far
as they relate to AMO's newly-launched Tecnis® One-Piece Intraocular
Lens. As part of this cross-license agreement, Alcon will make a payment
to AMO of $31 million and AMO will make a payment to Alcon of $10 million.
All other terms of the agreement are confidential. AMO expects to receive
the net cash proceeds of $21 million in the second quarter of 2008.

About Advanced Medical Optics (AMO):

AMO is focused on providing the full range of advanced refractive technologies
and support to help eye care professionals deliver optimal vision and
lifestyle experiences to patients of all ages. Products in the cataract
line include monofocal intraocular lenses (IOLs), phacoemulsification
systems, viscoelastics, and related products used in ocular surgery. AMO
owns or has the rights to such product brands as Tecnis®, Clariflex®
and Sensar® IOLs; Sovereign®, Sovereign® Compact and WhiteStar
Signature phacoemulsification systems with WhiteStar® technology;
Healon® viscoelastics and the Baerveldt® glaucoma shunt. Products
in the refractive line include wavefront diagnostic devices, femtosecond
lasers and associated patient interface devices; excimer laser vision
correction systems and treatment cards, and refractive implants. AMO brands
in the refractive business include iDesign, iFS, Star S4 IR®,
WaveScan Wavefront®, Advanced CustomVue, IntraLase®, IntraLasik®
and ReZoom®, Tecnis® Multifocal and Verisyse® IOLs. Products
in the eye care line include disinfecting solutions, enzymatic cleaners,
lens rewetting drops and artificial tears. Among the eye care product
brands the company possesses are COMPLETE®, COMPLETE® Blink-N-Clean®,
Consept®F, Consept® 1 Step, Oxysept® 1 Step, UltraCare®,
Ultrazyme®, Total Care and blink branded products. AMO
is based in Santa Ana, California, and employs approximately 4,000 worldwide.
The company has operations in 24 countries and markets products in approximately
60 countries.

Forward-Looking Statements

This press release contains forward-looking
statements about AMO, including statements related to payments expected
to be paid by the parties under the terms of the cross-licensing agreement.
All forward-looking statements in this press release represent AMO's judgment
only as of the date of this press release. Actual results may differ from
current expectations based on a number of factors, including, but not
limited to, unexpected delays in payment and non-compliance with the terms
of the agreement. Therefore, the reader is cautioned not to rely on these
forward-looking statements. AMO disclaims any intent or obligation to
update these forward-looking statements. Additional information concerning
these and other risk factors may be found in previous press releases issued
by AMO and AMO's public periodic filings with the Securities and Exchange
Commission, including the discussion under the heading "Risk Factors"
in AMO's 2007 Form 10-K filed in March 2008.